Initial characteristics, overall and by study group
| Characteristics . | Total . | Study group . | Comparison of the 3 groups . | ||
|---|---|---|---|---|---|
| n=225 . | BFM, n=88 . | SFOP, n=82 . | UKCCSG, n=55 . | ||
| n (%) . | n (%) . | n (%) . | n (%) . | P . | |
| Sex: male | 140 (62) | 61 (69) | 46 (56) | 33 (60) | .19 |
| Age, no. 10 years or older | 117 (52) | 47 (53) | 37 (45) | 33 (60) | .22 |
| Positivity for ALK antibody (82 MD) | 128/143 (90) | 44/51 (86) | 74/80 (93) | 10/12 (83) | .33 |
| Immunophenotype (35 MD) | <.001 | ||||
| T-markers | 135 (71) | 42 (59) | 61 (87) | 32 (65) | — |
| Null | 55 (29) | 29 (41) | 9 (13) | 17 (35) | — |
| B symptoms (1 MD) | 121 (54) | 41 (47) | 56 (68) | 24 (44) | .005 |
| Lymph nodes | 206 (92) | 80 (91) | 77 (94) | 49 (89) | .59 |
| Lymph nodes, mediastinal involvement | 81 (36) | 30 (34) | 32 (39) | 19 (35) | .77 |
| Extranodal disease | 154 (68) | 66 (75) | 49 (60) | 39 (71) | .09 |
| Skin lesion (s) | 59 (26) | 17 (19) | 27 (33) | 15 (27) | .13 |
| Bone lesion (s) | 32 (14) | 16 (18) | 10 (12) | 6 (11) | .39 |
| Marrow involvement | 17 (8) | 2 (2) | 13 (16) | 2 (4) | .002 |
| CNS disease | 3 (1) | 1 (1) | 0 (0) | 2 (4) | .25 |
| Soft-tissue mass | 33 (15) | 18 (19) | 10 (12) | 6 (10) | .23 |
| Visceral involvement including: | 97 (43) | 43 (49) | 28 (34) | 26 (47) | .17 |
| Spleen involvement | 42 (19) | 11 (13) | 17 (21) | 14 (25) | .13 |
| Liver involvement | 42 (19) | 19 (22) | 14 (17) | 9 (16) | .66 |
| Lung lesion | 28 (12) | 11 (13) | 11 (13) | 6 (11) | .91 |
| Other visceral involvement | 52 (23) | 28 (32) | 8 (10) | 16 (29) | .002 |
| St Jude staging | .53* | ||||
| Stage 1 | 19 (9) | 9 (10) | 6 (7) | 4 (7) | — |
| Stage 2 | 39 (17) | 15 (17) | 17 (21) | 7 (13) | — |
| Stage 3 | 147 (65) | 61 (69) | 46 (56) | 40 (73) | — |
| Stage 4 | 20 (9) | 3 (3) | 13 (16) | 4 (7) | — |
| Ann Arbor staging | .34* | ||||
| Stage 1 | 14 (6) | 7 (8) | 6 (7) | 1 (2) | — |
| Stage 2 | 42 (19) | 12 (14) | 19 (23) | 11 (20) | — |
| Stage 3 | 20 (9) | 5 (6) | 9 (11) | 6 (11) | — |
| Stage 4 | 149 (66) | 64 (73) | 48 (59) | 37 (67) | — |
| LDH (47 MD), 2× ULN or more | 18 (10) | 1 (1) | 16 (22) | 1 (3) | .001 |
| Characteristics . | Total . | Study group . | Comparison of the 3 groups . | ||
|---|---|---|---|---|---|
| n=225 . | BFM, n=88 . | SFOP, n=82 . | UKCCSG, n=55 . | ||
| n (%) . | n (%) . | n (%) . | n (%) . | P . | |
| Sex: male | 140 (62) | 61 (69) | 46 (56) | 33 (60) | .19 |
| Age, no. 10 years or older | 117 (52) | 47 (53) | 37 (45) | 33 (60) | .22 |
| Positivity for ALK antibody (82 MD) | 128/143 (90) | 44/51 (86) | 74/80 (93) | 10/12 (83) | .33 |
| Immunophenotype (35 MD) | <.001 | ||||
| T-markers | 135 (71) | 42 (59) | 61 (87) | 32 (65) | — |
| Null | 55 (29) | 29 (41) | 9 (13) | 17 (35) | — |
| B symptoms (1 MD) | 121 (54) | 41 (47) | 56 (68) | 24 (44) | .005 |
| Lymph nodes | 206 (92) | 80 (91) | 77 (94) | 49 (89) | .59 |
| Lymph nodes, mediastinal involvement | 81 (36) | 30 (34) | 32 (39) | 19 (35) | .77 |
| Extranodal disease | 154 (68) | 66 (75) | 49 (60) | 39 (71) | .09 |
| Skin lesion (s) | 59 (26) | 17 (19) | 27 (33) | 15 (27) | .13 |
| Bone lesion (s) | 32 (14) | 16 (18) | 10 (12) | 6 (11) | .39 |
| Marrow involvement | 17 (8) | 2 (2) | 13 (16) | 2 (4) | .002 |
| CNS disease | 3 (1) | 1 (1) | 0 (0) | 2 (4) | .25 |
| Soft-tissue mass | 33 (15) | 18 (19) | 10 (12) | 6 (10) | .23 |
| Visceral involvement including: | 97 (43) | 43 (49) | 28 (34) | 26 (47) | .17 |
| Spleen involvement | 42 (19) | 11 (13) | 17 (21) | 14 (25) | .13 |
| Liver involvement | 42 (19) | 19 (22) | 14 (17) | 9 (16) | .66 |
| Lung lesion | 28 (12) | 11 (13) | 11 (13) | 6 (11) | .91 |
| Other visceral involvement | 52 (23) | 28 (32) | 8 (10) | 16 (29) | .002 |
| St Jude staging | .53* | ||||
| Stage 1 | 19 (9) | 9 (10) | 6 (7) | 4 (7) | — |
| Stage 2 | 39 (17) | 15 (17) | 17 (21) | 7 (13) | — |
| Stage 3 | 147 (65) | 61 (69) | 46 (56) | 40 (73) | — |
| Stage 4 | 20 (9) | 3 (3) | 13 (16) | 4 (7) | — |
| Ann Arbor staging | .34* | ||||
| Stage 1 | 14 (6) | 7 (8) | 6 (7) | 1 (2) | — |
| Stage 2 | 42 (19) | 12 (14) | 19 (23) | 11 (20) | — |
| Stage 3 | 20 (9) | 5 (6) | 9 (11) | 6 (11) | — |
| Stage 4 | 149 (66) | 64 (73) | 48 (59) | 37 (67) | — |
| LDH (47 MD), 2× ULN or more | 18 (10) | 1 (1) | 16 (22) | 1 (3) | .001 |
Percentages may not add up to 100 because of rounding off.
MD indicates missing data; and —, not available.
Comparison of stages 1 and 2 with stages 3 and 4.